Direct answer
An injection pen OEM proposal should state what the supplier will deliver, what the buyer must provide and which decisions remain open. The most important boundaries are empty device versus filled medicine, appearance sample versus verified configuration, existing-platform customization versus mechanism development, and supplier documents versus market authorization. These distinctions affect cost, timing and the evidence needed for a release decision. A clear proposal does not have to claim every capability; it should identify the relevant activities and limitations for the exact project. Use this guide when a quotation sounds comprehensive but does not define its deliverables. Hytanbio project discussions should be tied to the intended configuration and a written brief, not an assumption that a catalog image, reference brand or broad OEM label establishes a finished medicine-device product.
Make project outputs and acceptance decisions explicit
For each stage, define the input, output and approval decision. A design review may produce a feasibility response and list of missing information, while an appearance prototype supports a different decision from a functional engineering sample. Tooling approval, pilot manufacturing, verification and commercial release should not be treated as one interchangeable milestone. Record whether any proposed change affects only artwork or also the container interface, user tasks, mechanism or delivery behavior. Identify the owner of each remaining test and the party permitted to accept its result. The quote should state what happens when a requirement changes after approval and which costs are affected. For peptide and insulin programs, keep formulation, filling and finished-product responsibilities visible. This turns a broad OEM discussion into a traceable sequence of decisions without promising that development and authorization are already complete.
- Proposed supply activities and explicit exclusions
- Purpose and revision of each sample
- Design, tooling, pilot and release milestones
- Buyer approvals and acceptance evidence
- Responsibility for formulation, filling and authorization
- Treatment of changes, deviations and unresolved questions
Procurement questions
These answers distinguish a proposed OEM device program from a finished medicine presentation. Use the written project specification and the exact current product labeling when confirming scope; they are not patient-use instructions.
Is private labeling the same as developing a new mechanism?
No. Artwork or packaging work and mechanism development can have different inputs, risks and evidence needs. The proposal should identify exactly which changes are included and which require separate engineering review.
Does receiving a prototype complete validation?
No. A prototype supports the decisions defined for that sample. Identify its configuration, test purpose and limitations, then keep outstanding verification, manufacturing and finished-product authorization tasks separate.
Why retain a written responsibility matrix?
It prevents a gap from being silently assigned to the other party. Record who supplies each input, owns each deliverable, reviews evidence and authorizes the next stage so the final project scope can be audited.
Sources and editorial scope
These sources identify evidence categories and reference scope; they do not certify a Hytanbio device or replace a project-specific assessment. Editorial check: . Prepared by Hytanbio Tech for B2B procurement.
Continue your device assessment
Peptide and insulin application guides · OEM/ODM project scope · Quality and evidence requests · Send a device project brief